1 GBD 2017 Pancreatic Cancer Collaborators: The global,
regional, and national burden of pancreatic cancer and its
attributable risk factors in 195 countries and territories, 19902017: a systematic analysis for the Global Burden of Disease
Study 2017. Lancet Gastroenterol Hepatol 4(12): 934-947, 2019.
PMID: 31648972. DOI: 10.1016/S2468-1253(19)30347-4
2 Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon
P, Truninger K, Ammann R, Cavallini G, Charnley RM, Uomo
G, Delhaye M, Spicak J, Drumm B, Jansen J, Mountford R,
Whitcomb DC and Neoptolemos JP: Clinical and genetic
characteristics of hereditary pancreatitis in Europe. Clin
Gastroenterol Hepatol 2(3): 252, 2004. PMID: 15017610. DOI:
10.1016/s1542-3565(04)00013-8
3 Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer.
Lancet 388(10039): 73-85, 2016. PMID: 26830752. DOI:
10.1016/S0140-6736(16)00141-0
4 Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA,
Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F,
Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler
MW and European Study Group for Pancreatic Cancer: A
randomized trial of chemoradiotherapy and chemotherapy after
resection of pancreatic cancer. N Engl J Med 350: 1200-1210,
2004. PMID: 15028824. DOI: 10.1056/NEJMoa032295
5 Vaccaro V, Sperduti I, Vari S, Bria E, Melisi D, Garufi C, Nuzzo
C, Scarpa A, Tortora G, Cognetti F, Reni M and Milella M:
Metastatic pancreatic cancer: Is there a light at the end of the
tunnel? World J Gastroenterol 21(16): 4788-4801, 2015. PMID:
25944992. DOI: 10.3748/wjg.v21.i16.4788
6 Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg
ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM,
Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD:
Improvements in survival and clinical benefit with gemcitabine
as first-line therapy for patients with advanced pancreas cancer:
a randomized trial. J Clin Oncol 15: 2403-2413, 1997. PMID:
9196156. DOI: 10.1200/JCO.1997.15.6.2403
7 Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski
K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K,
Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein
WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B
and Riess H: Adjuvant chemotherapy with gemcitabine vs
observation in patients undergoing curative-intent resection of
pancreatic cancer: a randomized controlled trial. JAMA 297:
267-277, 2007. PMID: 17227978. DOI: 10.1001/jama.297.3.267
8 Pasquinelli AE: MicroRNAs and their targets: recognition,
regulation and an emerging reciprocal relationship. Nat Rev Genet
13: 271-282, 2012. PMID: 22411466. DOI: 10.1038/nrg3162
9 Kozinn SI, Harty NJ, Delong JM, Deliyiannis C, Logvinenko T,
Summerhayes IC, Libertino JA, Holway AH and Rieger-Christ
KM: MicroRNA profile to predict gemcitabine resistance in
bladder carcinoma cell lines. Genes Cancer 4: 61-69, 2013.
PMID: 23946872. DOI: 10.1177/1947601913484495
10 Li H and Yang BB: Friend or foe: the role of microRNA in
chemotherapy resistance. Acta Pharmacol Sin 34: 870-879,
2013. PMID: 23624759. DOI: 10.1038/aps.2013.35
11 Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M,
Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S, Shiozaki
A, Ikoma H, Okamoto K, Ochiai T, Taniguchi H and Otsuji E:
Clinical impact of circulating miR-221 in plasma of patients
3202
12
13
14
15
16
17
18
19
20
21
22
23
with pancreatic cancer. Br J Cancer 108: 361-369, 2013. PMID:
23329235. DOI: 10.1038/bjc.2012.546
Zhao G, Zhang JG, Liu Y, Qin Q, Wang B, Tian K, Liu L, Li X,
Niu Y, Deng SC and Wang CY: miR-148b functions as a tumor
suppressor in pancreatic cancer by targeting AMPKα1. Mol
Cancer Ther 12: 83-93, 2013. PMID: 23171948. DOI: 10.1158/
1535-7163.MCT-12-0534-T
Chen WY, Liu WJ, Zhao YP, Zhou L, Zhang TP, Chen G and
Shu H: Induction, modulation and potential targets of miR-210
in pancreatic cancer cells. Hepatobiliary Pancreat Dis Int 11:
319-324, 2012. PMID: 22672828. DOI: 10.1016/s14993872(12)60168-4
Toyota Y, Iwama H, Kato K, Tani J, Katsura A, Miyata M,
Fujiwara S, Fujita K, Sakamoto T, Fujimori T, Okura R,
Kobayashi K, Tadokoro T, Mimura S, Nomura T, Miyoshi H,
Morishita A, Kamada H, Yoneyama H, Okano K, Suzuki Y and
Masaki T: Mechanism of gemcitabine-induced suppression of
human cholangiocellular carcinoma cell growth. Int J Oncol 47(4):
1293-1302, 2015. PMID: 26252371. DOI: 10.3892/ijo.2015.3118
Miyata M, Morishita A, Sakamoto T, Katsura A, Kato K,
Nishioka T, Toyota Y, Fujita K, Maeda E, Nomura T, Tani J,
Miyoshi H, Yoneyama H, Kobara H, Fujiwara S, Nishiyama N,
Iwama H, Himoto T, Hirashima M and Masaki T: MicroRNA
profiles in cisplatin-induced apoptosis of hepatocellular
carcinoma cells. Int J Oncol 47(2): 535-542, 2015. PMID:
26060089. DOI: 10.3892/ijo.2015.3036
Calabretta S, Bielli P, Passacantilli I, Pilozzi E, Fendrich V,
Capurso G, Fave GD and Sette C: Modulation of PKM
alternative splicing by PTBP1 promotes gemcitabine resistance
in pancreatic cancer cells. Oncogene 35: 2031-2039, 2016.
PMID: 26234680. DOI: 10.1038/onc.2015.270
Binenbaum Y, Na’ara S and Gil Z: Gemcitabine resistance in
pancreatic ductal adenocarcinoma. Drug Resist Updat 23: 55-68,
2015. PMID: 26690340. DOI: 10.1016/j.drup.2015.10.002
Hui YF and Reitz J: Gemcitabine: a cytidine analogue active
against solid tumors. Am J Health Syst Pharm 54: 162-170,
1997. PMID: 9117804. DOI: 10.1093/ajhp/54.2.162
Carpenelli G, Bucci G, D’Agnano I, Canese R, Caroli F, Raus
L, Brunetti E, Giannarelli E, Podo F and Carapella CM:
Gemcitabine treatment of experimental C6 glioma: the effects
on cell cycle and apoptotic rate. Anticancer Res 26: 3017-3024,
2006. PMID: 16886629.
Zhang C, Li H, Wang J, Zhang J and Hou X: MicroRNA-3383p suppresses cell proliferation, migration and invasion in
human malignant melanoma by targeting MACC1. Exp Ther
Med 18(2): 997-1004, 2019. PMID: 31316597. DOI:
10.3892/etm.2019.7644
Y Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR
and Dumontet C: Expression of a non-functional p53 affects the
sensitivity of cancer cells to gemcitabine. Int J Cancer 97(4):
439-445, 2002. PMID: 11802204. DOI: 10.1002/ijc.1628
Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum
J and Lawrence TS: Role of checkpoint kinase 1 in preventing
premature mitosis in response to gemcitabine. Cancer Res 65:
6835-6842, 2005. PMID: 16061666. DOI: 10.1158/0008-5472.
CAN-04-2246
Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale
F, Banzato F, D’Incalci M and Ubezio P: Cell cycle effects of
gemcitabine. Int J Cancer 93: 401-408, 2001. PMID: 11433406.
DOI: 10.1002/ijc.1351
Namima et al: MicroRNA Profile in Gemcitabine-treated PDAC Cells and Tumours
24 Rejiba S, Wack S, Aprahamian M and Hajri A: K-ras oncogene
silencing strategy reduces tumor growth and enhances
gemcitabine chemotherapy efficacy for pancreatic cancer
treatment. Cancer Sci 98: 1128-1136, 2007. PMID: 17489984.
DOI: 10.1111/j.1349-7006.2007.00506.x
25 Sherr CJ: G1 phase progression: cycling on cue. Cell 79: 551-555,
1994. PMID: 7954821. DOI: 10.1016/0092-8674(94)90540-1
26 Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B,
Harada N and Beger HG: Overexpression of cyclin D1 in human
pancreatic carcinoma is associated with poor prognosis. Cancer
Res 57: 1634-1637, 1997. PMID: 9134998.
27 Zhu HQ, Ma JB, Song X, Gao HJ, Ma CQ, Chang H, Li HG,
Liu FF, Lu J and Zhou X: Metformin potentiates the anticancer
activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo. Oncol Rep 36: 3488-3496,
2016. PMID: 27779693. DOI: 10.3892/or.2016.5187
28 Kornmann M, Ishiwata T, Itakura J, Tangvoranuntakul P, Beger
HG and Korc M: Increased cyclin D1 in human pancreatic
cancer is associated with decreased postoperative survival.
Oncology 55: 363-369, 1998. PMID: 9663429. DOI: 10.1159/
000011879
29 Chandler NM, Canete JJ and Callery MP: Caspase-3 drives
apoptosis in pancreatic cancer cells after treatment with
gemcitabine. J Gastrointest Surg 8: 1072-1078, 2004. PMID:
15585396. DOI: 10.1016/j.gassur.2004.09.054
30 Hamed SS, Straubinger RM and Jusko WJ: Pharmaco-dynamic
modeling of cell cycle and apoptotic effects of gemcitabine on
pancreatic adenocarcinoma cells. Cancer Chemother Pharmacol
72(3): 553-563, 2013. PMID: 23835677. DOI: 10.1007/s00280013-2226-6
31 Drakaki A and Iliopoulos D: MicroRNA-gene signaling
pathways in pancreatic cancer. Biomed J 36: 200-208, 2013.
PMID: 24225187. DOI: 10.4103/2319-4170.119690
32 Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell
JT, Jiang J, Schmittgen TD and Patel T: Involvement of human
micro-RNA in growth and response to chemotherapy in human
cholangiocarcinoma cell lines. Gastroenterology 130: 21132129, 2006. PMID: 16762633. DOI: 10.1053/j.gastro.
2006.02.057
33 Morishita A and Masaki T: miRNA in hepatocellular carcinoma.
Hepatology Res 45: 128-141, 2015. PMID: 25040738. DOI:
10.1111/hepr.12386
34 Yu J, Li A, Hong SM, Hruban RH and Goggins M: MicroRNA
alterations of pancreatic intraepithelial neoplasias. Clin Cancer
Res 18(4): 981-992, 2012. PMID: 22114139. DOI: 10.1158/
1078-0432.CCR-11-2347
35 Shu Z, Chen L and Ding D: miR-582-5P induces colorectal
cancer cell proliferation by targeting adenomatous polyposis
coli. World J Surg Oncol 14(1): 239, 2016. PMID: 27595705.
DOI: 10.1186/s12957-016-0984-4
Received May 28, 2020
Revised July 24, 2020
Accepted July 27, 2020
3203
...
論文の公開元へ
